导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 16.28% | 537/4773 |
| 近一周 | -0.60% | 1158/5465 |
| 近一月 | -4.77% | 3460/5421 |
| 近一季 | -8.61% | 3347/5231 |
| 近半年 | 9.51% | 607/4920 |
| 近一年 | 22.28% | 414/4394 |
| 近两年 | 110.45% | 531/2954 |
| 近三年 | 82.06% | 226/2253 |
| 成立以来 | 153.90% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.93% 1407/4961 |
35.29% 918/5312 |
- - |
- - |
| 2025 | 41.52% 734/4813 |
3.49% 1077/3635 |
2.58% 1478/4076 |
34.77% 1008/4524 |
-1.08% 2815/4813 |
| 2024 | 13.05% 1186/3463 |
-0.05% 1064/2808 |
-1.40% 1060/3014 |
11.14% 2550/3129 |
3.21% 852/3463 |
| 2023 | -10.90% 1347/2656 |
3.82% 1120/2280 |
-1.40% 482/2385 |
-10.25% 1974/2515 |
-3.03% 583/2655 |
| 2022 | -27.30% 1466/2207 |
-16.16% 1109/1919 |
7.92% 414/2016 |
-17.93% 1662/2113 |
-2.10% 1774/2208 |
| 2021 | 16.68% 262/1822 |
-2.51% 658/1255 |
15.92% 218/1330 |
-1.82% 541/1466 |
5.15% 303/1822 |
| 2020 | 59.18% 128/1250 |
4.93% 56/1028 |
28.31% 111/1067 |
8.15% 729/1164 |
9.31% 646/1184 |
| 2019 | 59.69% 56/1092 |
33.72% 134/754 |
-3.25% 379/804 |
13.55% 23/850 |
8.70% 297/918 |
| 2018 | -32.54% 533/834 |
- - |
- - |
- - |
-12.92% 494/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 富国中证高端制造指数增强型(LOF)A VS. 长安沪深300非周期A(740101) |